Surviving septic patients endotyped with a functional assay demonstrate active immune responses

Front Immunol. 2024 Oct 14:15:1418613. doi: 10.3389/fimmu.2024.1418613. eCollection 2024.

Abstract

Introduction: Sepsis is a complex clinical syndrome characterized by a heterogenous host immune response. Historically, static protein and transcriptomic metrics have been employed to describe the underlying biology. Here, we tested the hypothesis that ex vivo functional TNF expression as well as an immunologic endotype based on both IFNγ and TNF expression could be used to model clinical outcomes in sepsis patients.

Methods: This prospective, observational study of patient samples collected from the SPIES consortium included patients at five health systems enrolled over 17 months, with 46 healthy control patients, 68 ICU patients without sepsis, and 107 ICU patients with sepsis. Whole blood was collected on day 1, 4, and 7 of ICU admission. Outcomes included in-hospital and 180-day mortality and non-favorable discharge disposition defined by skilled nursing facility, long-term acute care facility, or hospice. Whole blood ELISpot assays were conducted to quantify TNF expression [stimulated by lipopolysaccharide (LPS)] and IFNγ expression (stimulated by anti-CD3/CD28 mAb), which were then used for assignment to one of four subgroups including an 'immunocompetent', 'immunosuppressed endotype', and two 'mixed' endotypes.

Results: Whole blood TNF spot-forming units were significantly increased in septic and CINS patients on days 4 and 7 compared to healthy subjects. In contrast, TNF expression per cell on days 1, 4, and 7 was significantly lower in both septic and critically ill non-septic (CINS) patients compared to healthy subjects. Early increases in total TNF expression were associated with favorable discharge disposition and lower in-hospital mortality. 'Immunocompetent' endotype patients on day 1 had a higher proportion of favorable to non-favorable discharges compared to the 'immunosuppressed' endotype. Similarly, 'immunocompetent' endotype patients on day 4 had a higher in-hospital survival compared to the 'immunosuppressed' endotype patients. Finally, among septic patients, decreased total TNF and IFNγ expression were associated with 180-day mortality.

Conclusions: Increased ex vivo whole blood TNF expression is associated with improved clinical outcomes. Further, the early 'immunocompetent' endotype is associated with favorable discharge and improved in-hospital and 180-day survival. The ability to functionally stratify septic patients based on blood cell function ex vivo may allow for identification of future immune modulating therapies.

Keywords: IL-6; critical illness; late mortality; prediction modeling; procalcitonin.

Publication types

  • Observational Study
  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Biomarkers / blood
  • Female
  • Hospital Mortality
  • Humans
  • Intensive Care Units
  • Interferon-gamma* / blood
  • Interferon-gamma* / metabolism
  • Male
  • Middle Aged
  • Prospective Studies
  • Sepsis* / blood
  • Sepsis* / immunology
  • Sepsis* / mortality
  • Tumor Necrosis Factor-alpha* / blood

Substances

  • Interferon-gamma
  • Tumor Necrosis Factor-alpha
  • Biomarkers

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. AP reports institutional support for salary from a National Institute of General Medical Sciences training grant “Host Response to Trauma Research Training Program” (5T32GM008478-30). EB reports institutional support for salary from a National Institute of General Medical Sciences training grant “Host Response to Trauma Research Training Program” (5T32GM008478-30). ELB reports institutional support for salary from a National Institute of General Medical Sciences training grant in burns, trauma and sepsis (T32 GM-008721) (PAE). CB is supported by grants from the Deutsche Forschungsgemeinschaft (German Research Foundation) (BE 7016/1-1). MG reports institutional support for salary from the National Institute of General Medical Sciences (R01 GM-124156) and the Department of Defense (G102983-6263608307-1). VP reports institutional support for salary from a National Institute of General Medical Sciences training grant in burns, trauma and sepsis (T32 GM-008721) (PAE). TL is supported by K23 GM-140268(TJL) and R01 GM-149657 (TJL) from the National Institute of General Medical Sciences. PE is supported by grants R35 GM-140806, T32 GM-008721 and RM GM-139690 awarded by the National Institute of General Medical Sciences. SB is funded by R35 GM-134880 from the National Institute of General Medical Sciences. VB is funded by R35 GM-134880 from the National Institute of General Medical Sciences. TG is funded by R35 GM-140881 from the National Institute of General Medical Sciences and the recipient of a Research Career Scientist award (IK6BX006192) from the Department of Veteran Affairs. LM is supported by NIH grants RM1 GM-139690, R01GM-132364 and RF1 NS128626.